Yttrium-90-labeled microsphere (local beta-radiation delivery system)

The entry "Tumor tissue via local beta-radiation emission from embedded yttrium‑90-labeled microspheres" does not refer to a molecular or cellular therapeutic target in the canonical sense. Instead, it describes a **drug delivery method** (radioembolization) using **yttrium-90-labeled microspheres** to deposit targeted beta-radiation into tumor tissue. These microspheres are administered via the hepatic artery to exploit the preferential blood supply of liver tumors; upon lodging in the tumor vasculature, they locally emit beta radiation, causing tumor cell death while typically sparing surrounding healthy tissue[1][2][3][4][6]. This method is used primarily to treat unresectable primary or metastatic liver tumors (such as hepatocellular carcinoma and some metastatic colorectal cancers), and is sometimes combined with other systemic therapies[1][4]. **This is not a specific molecular target such as a receptor, enzyme, or protein, but rather a localized radiation delivery approach; therefore, the entry is not correctly formatted as a drug target.**

Other names

Yttrium-90 microsphereY-90 microsphereY-90-labeled microsphereradioembolization particleselective internal radiation therapy (SIRT) microsphere

Local delivery of beta-radiation via microsphere embolization